7.67

1.67% -0.13

After Hours: 7.61 -0.06 -0.78%

Upstream Bio Inc (UPB)

Overview News Price History Discussions Forecast

Upstream Bio Inc stock is traded at $7.67, with a volume of 941.65K. It is down -1.67% in the last 24 hours and down -70.50% over the past month. Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.

Previous Close:

$7.80

Open:

$7.64

24h Volume:

941.65K

Relative Volume:

0.83

Market Cap:

$414.48M

Revenue:

$2.22M

Net Income/Loss:

$-40.51M

P/E Ratio:

-5.9703

EPS:

-1.2847

Net Cash Flow:

$-46.53M

1W Performance:

-2.91%

1M Performance:

-70.50%

6M Performance:

-61.59%

1Y Performance:

-9.45%

1-Day Range:

$7.40

$7.78

1-Week Range:

$7.25

$8.07

52-Week Range:

$5.14

$33.68

Upstream Bio Inc Stock (UPB) Company Profile

Name

Upstream Bio Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

781-208-2466

Address

890 WINTER STREET, SUITE 200, WALTHAM

Employee

Twitter

Next Earnings Date

Latest SEC Filings

UPB's Discussions on Twitter

Compare UPB vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
UPB Upstream Bio Inc	7.67	421.50M	2.22M	-40.51M	-46.53M	-1.2847
VRTX Vertex Pharmaceuticals Inc	460.82	121.40B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	764.93	83.25B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	728.11	46.39B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	320.51	43.41B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	292.94	33.09B	5.36B	287.73M	924.18M	2.5229

Upstream Bio Inc Stock (UPB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-18-25	Initiated	Mizuho	Outperform
Nov-18-25	Initiated	Evercore ISI	Outperform
Oct-14-25	Initiated	Truist	Buy
Nov-05-24	Initiated	JP Morgan	Overweight
Nov-05-24	Initiated	Piper Sandler	Overweight
Nov-05-24	Initiated	TD Cowen	Buy
Nov-05-24	Initiated	William Blair	Outperform

View All

Upstream Bio Inc Stock (UPB) Latest News

Mar 04, 2026

RSI Check: Can Upstream Bio Inc outperform in the next rallyWeekly Trade Summary & Weekly Chart Analysis and Guides - baoquankhu1.vn

Mar 04, 2026

UPB: Verekitug shows best-in-class efficacy and safety, advancing to phase 3 with quarterly dosing - TradingView

Mar 04, 2026

CEO Rand Sutherland hosts live conference fireside chat, Upstream Bio, Inc. asserts - Traders Union

Mar 04, 2026

Upstream Bio (UPB) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat

Mar 04, 2026

Mar 03, 2026

Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Mar 03, 2026

Mar 01, 2026

Upstream Bio presents additional Phase 2 data for verekitug By Investing.com - Investing.com South Africa

Mar 01, 2026

Upstream Bio says primary endpoint showed reduction of -1.95 in nasal polyp score - marketscreener.com

Mar 01, 2026

Upstream Bio Says Primary Endpoint Showed Reduction of -1.95 in Nasal Polyp Score - TradingView

Mar 01, 2026

Upstream Bio Presents Additional Analyses from the Phase 2 - GlobeNewswire

Mar 01, 2026

Upstream Bio, Inc. unveils new analyses from VIBRANT Phase 2 trial at AAAAI2026 - Traders Union

Mar 01, 2026

Feb 28, 2026

UPB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Feb 28, 2026

Feb 27, 2026